Group 1 - The core issue is the sudden shift in South China Biological's profit forecast from "expected profit" to "expected loss," leading to a significant drop in stock price and market value [1] - The company reported a reduction in sales revenue by 0.14 billion and an unexpected increase in bad debt provisions by 0.21 billion, totaling a financial adjustment of 0.35 billion [1] - The company's internal control deficiencies and disclosure violations are identified as the root causes of this crisis, resulting in substantial losses for thousands of investors [1] Group 2 - Prior to the profit warning, South China Biological announced a plan to invest 300 million in wealth management, which now appears contradictory given the financial turmoil [2] - This juxtaposition highlights the management's negligence towards shareholder interests, focusing instead on personal financial gains [2] - The management's short-sighted actions have raised doubts about the company's future and its commitment to shareholder value [2] Group 3 - The company is urged to take immediate actions, including suspending the wealth management plan and reallocating those funds for share buybacks to restore market confidence [3] - Management is encouraged to increase their shareholdings to demonstrate commitment and responsibility towards shareholders [3] - A thorough investigation into the disclosure violations is recommended to rebuild trust with investors [3] Group 4 - The incident underscores the importance of maintaining integrity in the A-share market, as such drastic profit changes should not jeopardize a listed company's status [3] - Share buybacks are suggested as a direct and effective measure to stabilize stock prices and enhance the company's market image [3] - Taking decisive actions is crucial for South China Biological to regain investor confidence and ensure its survival in the capital market [3]

Core Viewpoint - Nanhua Biological (000504.SZ) significantly revised its 2024 annual performance forecast from a profit of 12.5 million to 15.5 million yuan to a loss of 19 million to 21 million yuan, triggering delisting risk warning conditions [1] Group 1: Performance Revision - The company’s 2024 net profit and net profit after deducting non-recurring gains and losses are both negative, with operating revenue below 300 million yuan, leading to a "*ST" designation for its stock [1] - The revision was attributed to return risks primarily related to the sales of the company's beauty products, as prior profit announcements were made before a comprehensive audit [5] Group 2: Business Transformation - Nanhua Biological has been transitioning towards beauty and anti-aging sectors, which are key areas of its recent business strategy, while previously being involved in real estate, media, biomedicine, and energy-saving industries [5] - The company has faced delisting risk warnings multiple times in the past due to consecutive years of losses, specifically in 2010, 2013, 2016, and 2019 [5] Group 3: Management and Control - The frequent changes in the company's business focus are linked to changes in its controlling shareholders, although the company asserts that there are no internal management issues or control deficiencies [5]

南华生物医药股份有限公司 关于公司股票交易可能被实施退市风险警示的第二次提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或者重大遗漏。 特别提示： 南华生物医药股份有限公司（以下简称"公司"）于 2025 年 4 月 22 日对外披露了《关 于 2024 年年度业绩预告修正暨可能被实施退市风险警示的公告》，预计公司 2024 年度净利 润、扣除非经常性损益后的净利润均为负值且扣除后营业收入低于 3 亿元，根据《深圳证券 交易所股票上市规则》第 9.3.1 条第（一）项规定，在公司 2024 年年度报告披露后，公司股 票交易可能被实施退市风险警示（股票简称前冠以"*ST"字样），敬请广大投资者注意投 资风险。 证券代码：000504 证券简称：南华生物 公告编号：2025-012 一、公司股票交易可能被实施退市风险警示的情况说明 1 公司已于 2025 年 4 月 22 日在《中国证券报》《证券时报》《上海证券报》 《证券日报》和巨潮资讯网（www.cninfo.com.cn）上披露《关于 2024 年年度业 绩预告修正暨可能被实施退市风险警示的公告》（公告编号： ...

4月22日，南华生物开盘即一字跌停，报8.11元，总市值为26.76亿元。 | 9.07 | | | | --- | --- | --- | | 9.01 | | | | 8.95 | | | | 8,88 | | | | 8.82 | | | | 8.75 | | | | 8.69 | | | | 8.62 | | | | 8,56 | | | | 8.50 | | | | 8.43 | | | | 8,37 | | | | 8.30 | | | | 8.24 | | | | 8.17 | | | | 8,11 | | | | 04/22 | 11:00 | 11:30 | 这一股价变动主要源于公司前一日晚间发布的业绩预告修正公告，即2024年归属于上市公司股东的净利润由预盈1250万–1550万元修正为预亏1900万–2100万 元。 业绩大变脸 | 项目 | 本报告期 | | 上年同期 | 是否修 | | --- | --- | --- | --- | --- | | | 原预计 | 最新预计 | | 正 | | 归属于上市公司 | 盈利: 1,250 万元 | 亏损:1,900 万 元 -2,100 ...

南华生物：修正2024年度业绩预告 公司股票可能被实施退市风险警示 智通财经4月21日电，南华生物(000504.SZ)发布2024年度业绩预告修正公告，预计净利润为亏损1900万 元-2100万元。公司原预计净利润为盈利1250万元–1550万元。公司预计公司2024年度净利润、扣除非经 常性损益后的净利润均为负值且扣除后营业收入低于3亿元，根据《深圳证券交易所股票上市规则》第 9.3.1条第（一）项规定，在公司2024年年度报告披露后，公司股票交易可能被实施退市风险警示（股票 简称前冠以"*ST"字样），敬请广大投资者注意投资风险。 ...

一、本期业绩预计情况 （一）业绩预告期间：2024 年 1 月 1 日至 2024 年 12 月 31 日 （二）前次业绩预告情况 公司于 2025 年 1 月 22 日对外披露了《2024 年年度业绩预告》（公告编号： 证券代码：000504 证券简称：南华生物 公告编号：2025-011 南华生物医药股份有限公司 关于 2024 年年度业绩预告修正暨可能被实施退市风险警示的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 重要内容提示： 南华生物医药股份有限公司（以下简称"公司"）预计公司 2024 年度净利润、扣除非 经常性损益后的净利润均为负值且扣除后营业收入低于 3 亿元，根据《深圳证券交易所股 票上市规则》第 9.3.1 条第（一）项规定，在公司 2024 年年度报告披露后，公司股票交易 可能被实施退市风险警示（股票简称前冠以"*ST"字样），敬请广大投资者注意投资风 险。 | 2025-002），前次业绩预告具体情况如下： | | --- | | 项目 | | 本报告期 | | 上年同期 | | | --- | --- | --- | -- ...

南华生物（000504）发布2024年度业绩预告修正公告，预计净利润为亏损1900万元-2100万元。公司原 预计净利润为盈利1250万元–1550万元。 ...

Core Viewpoint - Nanhua Bio's stock closed at 9.01 yuan, down 2.17%, with a latest price-to-book ratio of 11.96 and a total market capitalization of 2.974 billion yuan [1] Financial Performance - For the third quarter of 2024, Nanhua Bio reported operating revenue of 92.4171 million yuan, a year-on-year decrease of 11.78% - The net profit was -8,410,757.01 yuan, reflecting a year-on-year decline of 1828.05% - The sales gross margin stood at 68.03% [1] Market Activity - On April 21, 2024, Nanhua Bio experienced a net outflow of main funds amounting to 6.9602 million yuan, with a total outflow of 8.7643 million yuan over the past five days [1] Business Segments - Nanhua Bio operates in two main sectors: "Biopharmaceuticals" and "Energy Conservation and Environmental Protection" - The "Biopharmaceuticals" segment includes services for the separation, cultivation, and storage of stem cells and immune cells, as well as research on downstream products and clinical applications - The "Energy Conservation and Environmental Protection" segment encompasses energy-saving engineering and product R&D sales, comprehensive sewage treatment for special industries, investment and operation of distributed energy stations, and comprehensive energy-saving project investment and operation [1] Valuation Metrics - Nanhua Bio's PE (TTM) is -80.21, and its static PE is -105.55, with a price-to-book ratio of 11.96, compared to industry averages of 46.70 (TTM PE) and 42.96 (static PE) [2]

4月17日，南华生物今日收盘9.31元，上涨1.75%，最新市净率12.36，总市值30.73亿元。 截至2024年三季报，共有3家机构持仓南华生物，其中基金3家，合计持股数6.86万股，持股市值0.01亿 元。 序号股票简称PE(TTM)PE(静)市净率总市值(元)5南华生物-82.88-109.0612.3630.73亿行业平均 45.4042.223.36141.62亿行业中值47.4835.522.4848.62亿1普瑞眼科-185.6423.202.8062.17亿2何氏眼 科-148.0245.381.4928.84亿3迪安诊断-93.1128.031.2286.18亿4光正眼科-90.07214.007.2619.81亿6创新医 疗-41.80-41.802.2139.27亿7国际医学-33.45-32.523.28119.80亿8嘉和美康-27.12-27.122.2840.67亿9皓宸医 疗-22.13-22.794.8021.50亿10美迪西-11.96-11.961.6137.78亿11和元生物-11.16-11.161.9436.28亿 来源：金融界 南华生物医药股份有限公司主要从事" ...

3月31日，南华生物今日收盘9.51元，下跌1.86%，最新市净率12.62，总市值31.39亿元。 资金流向方面，3月31日，南华生物主力资金净流出679.71万元，近5日总体呈流出状态，5日共流出 345.07万元。 南华生物医药股份有限公司主要从事"生物医药"和"节能环保"两个板块的业务。公司"生物医药"板块业 务包括干细胞和免疫细胞的分离、培养、储存服务及其下游产品和临床应用的研究；公司"节能环保"板 块业务包括节能工程及产品研发销售、特种行业污水综合治理、分布式能源站投资经营、综合节能项目 投资运营等。 最新一期业绩显示，2024年三季报，公司实现营业收入9241.71万元，同比-11.78%；净利润-8410757.01 元，同比-1828.05%，销售毛利率68.03%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)6南华生物-84.66-111.4012.6231.39亿行业平均 51.1045.983.69162.70亿行业中值44.6136.882.7549.71亿1普瑞眼科-182.2922.792.7561.04亿2何氏眼 科-160.2749.131.6131.23亿3迪安 ...